Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, September 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 30 news outlets
blogs: 3 blogs
twitter: 169 X users
video: 1 YouTube creator

guideline: 4 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 4 podcasts

Readers on

mendeley: 228 Mendeley

So far, Altmetric has seen 3 posts from 3 blogs.

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer

Recent Press Highlights, 18 Feb 2026

Proceedings of the National Academy of Sciences, Volume 123, Issue 8, February 2026. SignificanceRadical cystectomy—surgical…

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

Physician's Weekly, 28 Sep 2024

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without…

RCT: Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improved Survival in Muscle-Invasive Bladder Cancer

SPECIALTIES, 18 Sep 2024

Background: Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligi…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.